Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04767035
Other study ID # MELT-100-002
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date December 1, 2020
Est. completion date January 14, 2021

Study information

Verified date February 2021
Source Melt Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Pivotal Phase 1, Randomized, Single-Dose, 4-Period, Crossover Relative Bioavailability Study of MELT-100, IV Midazolam, and IV Ketamine under Fasted Conditions in Healthy Volunteers


Description:

A Pivotal Phase 1, Randomized, Single-Dose, 4-Period, Crossover Relative Bioavailability Study of 2 doses of 3.5mgMELT-100, IV Midazolam, and IV Ketamine 18mg under Fasted Conditions in Healthy Volunteers


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date January 14, 2021
Est. primary completion date January 14, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 55 Years to 80 Years
Eligibility Inclusion Criteria: - 1. Able to understand and voluntarily consent to participation in this study and provides written informed consent before the start of any study-specific procedures. 2. Healthy adult male or female at least 55 years of age. 3. Negative test for SARS-CoV2 (COVID-19) 4. Normally active and otherwise judged to be in good health on the basis of medical history and physical examination. 5. Has vital signs (measured sitting after a minimum 3 minutes of rest) at Screening within the following ranges: heart rate: 40 to 100 bpm; systolic blood pressure (BP): 90 to145 mmHg; diastolic BP: 50 to 95 mmHg. Out-of-range vital signs may be repeated once. 6. Has a body temperature =37.7 degrees C 7. Body weight at least 55 kg 8. Body mass index (BMI) 18.0 to 32.0 kg/m2 (inclusive) 9. Female subjects are eligible only if the following applies: Surgically sterile (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy), or postmenopausal (confirmed with serum FSH at Screening) 10. Male subjects must either be surgically sterile (vasectomy at least 3 months prior to first dose) or agree to use an acceptable method of birth control (see Section 4.4) from Screening through EOS. 11. Is willing and able to remain in the study unit for the entire duration of each confinement period. Exclusion Criteria: - 1. History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, ophthalmologic, dermatologic, neurologic, oncologic, or psychiatric disease or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the subject or the validity of the study results. 2. Has a history of glaucoma, asthma, chronic obstructive pulmonary disease, or thyroid disease. 3. History and/or family history of congenital long QT syndrome, unexplained syncope, or other additional risks for Torsade de Pointes, or sudden premature death. 4. Clinically significant illnesses within 4 weeks of the administration of study medication (including flu, flu-like symptoms, diarrhea, vomiting, fever, sore throat) or acute illness at the time of either the pre-study medical evaluation or dosing. 5. Has been in contact with someone within the last month who has tested positive for SARS-CoV-2. 6. History of COVID-19. 7. Clinically significant surgery within 4 weeks prior to the administration of the study medication. 8. Has participated in another clinical trial (randomized subjects only) within 30 days before the first dose of study medication. 9. An active malignancy of any type or has been diagnosed with cancer within 5 years prior to Screening (excluding squamous or basal cell carcinoma of the skin). 10. History or presence of allergic or adverse response to midazolam, ketamine, 11. Use of any over-the-counter (OTC) medication (including nutritional or dietary supplements, herbal preparations, or vitamins) within 14 days before the first dose of study medication until the EOS without evaluation and approval by the Investigator. 12. Use of any prescription medication, except statin drugs or hormonal replacement therapy, from 14 days before the first dose of study medication until the EOS without evaluation and approval by the Investigator. 13. Have had a depot injection or an implant of any drugs 3 months prior to administration of study medication. 14. Has been treated with any known drugs that are moderate or strong inhibitors/inducers of cytochrome P450 (CYP) enzymes (e.g., barbiturates, phenothiazines, cimetidine, carbamazepine) within 30 days before the first dose of study medication, and that, in the Investigators judgment, may impact subject safety or the validity of the study results. Specifically, the use of any drugs known to inhibit CYP2C9 and CYP3A4 enzymes (for example, amiodarone, fluconazole, ketoconazole, itraconazole, clarithromycin, ritonavir, erythromycin) or any drugs that are highly protein-bound (for example, warfarin, cyclosporine, amphotericin B) within 30 days prior to the first dose of study medication, and that in the Investigator's judgment may impact subject safety or the validity of the study results. 15. Blood or plasma donation within 30 days before the first dose of study medication until the EOS. It is recommended that blood/plasma donations not be made for at least 30 days after the EOS. 16. Has any prior history of substance abuse or treatment (including alcohol). 1. History of significant alcohol abuse within 6 months of Screening or any indication of the regular use of more than 2 units of alcohol per day (1 unit = 50 mL of wine or 360 mL of beer or 45 mL of alcohol 40%). 2. History of use of marijuana within 3 months of Screening or drugs such as cocaine, phencyclidine (PCP), within 1 year of Screening. 17. Smoking or use of tobacco- or nicotine-containing products within 60 days before the first dose of study medication until the EOS Note: Nonsmokers are preferred for this study. 18. Any food allergy, intolerance, restriction, or special diet that, in the opinion of the Investigator, contraindicates the subjects participation in this study. 19. Has been on a significantly abnormal diet during the 4 weeks preceding the first dose of study medication. 20. Consumption of beverages or foods that contain alcohol, poppy seeds, broccoli, Brussels sprouts, pomegranate, star fruit, char-grilled meat, or caffeine/xanthine from 48 hours before the first dose of study medication until the EOS. Subject must not consume grapefruit, orange, or apple juice from 7 days before the first dose of study medication until the EOS. Subjects will be instructed not to consume any of the above products; however, allowance for an isolated single incidental consumption may be evaluated and approved by the study Investigator based on the potential for interaction with the study drug. 21. Engagement in strenuous exercise from 48 hours before the first dose of study medication until the EOS. 22. A clinically significant abnormal finding on the physical examination, medical history, or clinical laboratory results at Screening.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
midazolam / ketamine sublingual tablet
sublingual tablet

Locations

Country Name City State
United States Worldwide Clinical Trials San Antonio Texas

Sponsors (2)

Lead Sponsor Collaborator
Melt Pharmaceuticals Worldwide Clinical Trials

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cmax Maximum Concentration 24 hours
Primary AUClast Area under the curve 24 hours
See also
  Status Clinical Trial Phase
Recruiting NCT03692390 - Virtual Reality vs. Standard-of-Care for Comfort Before and After Sedation in the Emergency Department N/A
Completed NCT02145169 - Inhaled Nitrous Oxide for the Prevention of Emergence Reaction During Ketamine Administration in Adults, a Pilot Study N/A
Recruiting NCT05595798 - EEG Spectral Pattern of Deep Sedation-induced Airway Adverse Effects
Completed NCT01260662 - Randomized Clinical Trial of Propofol, 1:1 and 4:1 Combination of Propofol and Ketamine for Procedural Sedation Phase 4
Completed NCT00784498 - Procedural Sedation Using Propofol Versus Midazolam/Ketamine in the Adult Emergency Department Phase 4
Completed NCT00327392 - A Safety Study of AQUAVAN® (Fospropofol Disodium) Injection for Sedation During Minor Surgical Procedures. Phase 2/Phase 3
Recruiting NCT04873596 - Dexmedetomidine and Midazolam Nebulization as Sedation During Cesarean Delivery in Pre-eclampsia Phase 2
Completed NCT03329014 - A Trial of Intranasal Remimazolam Pharmacokinetics, Pharmacodynamics, Safety and Bioavailability Phase 1
Recruiting NCT06414395 - The Effects of Different Loading Doses of Dexmedetomidine on The Bispectral Index-Guided Propofol Sedation in Patients Undergoing Advanced Upper Gastrointestinal Endoscopic Procedures: A Randomized Control Study Phase 4
Recruiting NCT03860831 - Intranasal Ketamine and Midazolam Mixture for Procedural Sedation in Children With Mental Disabilities: Phase 1
Completed NCT00869440 - Dose-Finding Safety Study Evaluating Remimazolam (CNS 7056) in Patients Undergoing Diagnostic Upper GI Endoscopy Phase 2
Not yet recruiting NCT05757622 - Electroencephalogram Based Real-Time Sedation Level Prediction
Completed NCT03799783 - The Use of Dexmedetomidine for EEG Sedation in Children With Behavioural Disorders Phase 2
Completed NCT02180737 - Dexmedetomidine for Sedation During Radiological Interventional Procedures Phase 4
Not yet recruiting NCT01227174 - Safety and Efficacy of Propofol Only Sedation in Oral and Maxillofacial Surgery Phase 4
Recruiting NCT03499886 - Low-Dose Intravenous Ketamine Bolus Versus Conventional Technique Phase 2/Phase 3
Completed NCT03747432 - Comparison of Procedural Sedation With Propofol and Dexmedetomidine During Transcatheter Aortic Valve Implantation Phase 4
Recruiting NCT06203522 - Factors Associated With Successful Completion of MRI in Children Undergoing a Vigil Sedation With Dexmedetomidin
Withdrawn NCT05783492 - INK Feasibility Study Phase 3
Recruiting NCT04686448 - Ketofol Versus Fenofol as Procedural Sedation for Carpal Tunnel Release Phase 1/Phase 2